Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-center, Cross-over, Comparative Bioavailability Study of DOXIL/CAELYX Manufactured at a New Site in Patients With Advanced or Refractory Ovarian or Breast Cancer

NCT05567601 is registered in ClinicalTrials.gov with Baxter Healthcare Corporation as lead sponsor.

NCT NCT05567601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05567601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-center, Cross-over, Comparative Bioavailability Study of DOXIL/CAELYX Manufactured at a New Site in Patients With Advanced or Refractory Ovarian or Breast Cancer
Lead sponsor
Baxter Healthcare Corporation
Phase
Phase 1
Overall status
Completed
Start date
December 16, 2023
Completion date
June 21, 2024
Enrollment
36 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related kaposi sarcoma, metastatic breast cancer, multiple myeloma, ovarian cancer